Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

IntegenX Launches New GlobalFiler® Express Cartridges for RapidHIT® System

Published: Tuesday, February 18, 2014
Last Updated: Tuesday, February 18, 2014
Bookmark and Share
IntegenX has completed the Developmental Validation of GlobalFiler Express reagents from Life Technologies on the RapidHIT System in accordance with SWGDAM guidelines.

IntegenX Inc. announced the launch of GlobalFiler® Express cartridges for the RapidHIT™ System, providing DNA profiles with 24-loci in less than two hours with less than five minutes hands-on time. 

The RapidHIT GlobalFiler Express cartridges contain Life Technologies’ NDIS-approved GlobalFiler Express Kit which has all DNA markers commonly used in most international databases, including all markers recommended for inclusion by the CODIS Core Loci Working Group. The RapidHIT GlobalFiler Express cartridges feature a flexible design, allowing operators to run from one to seven samples in a single run, as well as a room temperature cartridge storage protocol.

IntegenX completed the Developmental Validation of the GlobalFiler Express cartridges with the RapidHIT System for buccal swabs with a highly successful CODIS profile generation rate. Completion of Scientific Working Group for DNA Analysis Methods (SWGDAM) Developmental Validation is a key milestone necessary for the commercialization of human DNA identification systems in forensics, law enforcement, defense, homeland security, and intelligence community applications: the RapidHIT is the only Rapid DNA System to have met such a milestone.

In addition to Developmental Validation data for buccal swabs, IntegenX has generated data demonstrating the RapidHIT System readily analyzes samples routinely recovered from crime scenes, such as blood, saliva, and semen. These applications dramatically expand the utility of the RapidHIT System and provide a fast DNA-based crime scene investigation and rapid lead identification capability for the law enforcement, defense, and intelligence communities worldwide. Data will be presented at the 66th Annual AAFS meeting, February 17-22, Seattle, Washington.

“The combination of the extremely high discrimination power of the large GlobalFiler Express multiplex and the capability of an expedited sample-to-answer with RapidHIT DNA technology should be a powerful tool to extend the utility of DNA typing both outside and within the laboratory,” said Bruce Budowle, Ph.D., executive director of the Institute of Applied Genetics at the University of North Texas Health Science Center (UNTHSC).

“We’re thrilled at the full commercial global launch of the RapidHIT GlobalFiler Express cartridges, and the new flexible format that allows operators to decide how many samples to include per run. The Developmental Validation of the GlobalFiler Express cartridges under SWGDAM guidelines is an important milestone. Offering Life Technologies’ most advanced NDIS-approved chemistry on the RapidHIT will be of great value to the US and worldwide forensic communities,” commented Robert Schueren, president and chief executive officer of IntegenX.

“The superior quality of the data obtained from GlobalFiler Express kits has proven to be a transformative solution for forensic labs,” said Nadia Altomare, vice president and general manager, Human Identification, for Thermo Fisher Scientific. “Our partnership with IntegenX brings together the industry’s most powerful chemistry and the leading rapid platform to help forensic laboratories and law enforcement agencies solve and prevent crimes.”

The IntegenX RapidHIT System fully automates and integrates all steps necessary to generate a DNA profile in less than two hours. With less than five minutes of hands-on time, an operator can generate up to seven complete DNA profiles. RapidHIT System DNA profiles are completely compatible with standard databases that contain previously generated profiles from reference and crime scene sources. Combining ease of use and rapid turnaround time for DNA human identification will have a high impact toward ensuring the safety of our communities.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Microsample Prep Company IntegenX Inc. Raises $15.6M, Acquires GenVault Corporation
Company announces closing of transaction and a $15.6M round of financing led by Domain Associates with participation from returning investors.
Monday, February 07, 2011
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Self-Propelled Powder to Stop Bleeding
UBC researchers have created the first self-propelled particles capable of delivering coagulants against the flow of blood to treat severe bleeding, a potentially huge advancement in trauma care.
Five New Genetic Variants Linked to Brain Cancer Identified
The biggest ever study of DNA from people with glioma – the most common form of brain cancer – has discovered five new genetic variants associated with the disease.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Probing the Forces Involved in Creating The Mitotic Spindle
Scientists at The Rockefeller University reveal new insights into the mechanical forces that govern elements of the mitotic spindle formation.
Identifying Cancer’s Food Sensors May Help to Halt Tumour Growth
Oxford University researchers have identified a protein used by tumours to help them detect food supplies. Initial studies show that targeting the protein could restrict cancerous cells’ ability to grow.
Fatty Liver Disease and Scarring Have Strong Genetic Component
Researchers say that hepatic fibrosis, which involves scarring of the liver that can result in dysfunction and, in severe cases, cirrhosis and cancer, may be as much a consequence of genetics as environmental factors.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos